Halozyme Therapeutics (HALO) Tops Q2 EPS by 6c, Offers Guidance

Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of $0.53, $0.06 better than the analyst estimate of $0.47. Revenue for the quarter came in at $152.4 million versus the consensus estimate of $138.63 million.

GUIDANCE:

Halozyme Therapeutics sees FY2022 EPS of $2.10-$2.25, versus the consensus of $2.23. Halozyme Therapeutics sees FY2022 revenue of $655-685 million, versus the consensus of $610.9 million.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance